EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of Left Ventricular Assist Devices (LVADs) as destination therapy in the UK: An economic modelling study

Tuba Saygın Avşar iD, Louise Jackson, Pelham Barton, Sophie Beese, Hoong S Lim, David Quinn iD, Malcolm Price, David J Moor

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0312912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tuba Saygın Avşar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Health Research, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Heart-Assist Devices, Cost-Benefit Analysis, Heart Failure, Models, Economic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Left Ventricular Assist Devices (LVADs) for destination therapy (DT) are used in many countries but in some, like the UK, LVADs are not commissioned due to uncertainty around their cost-effectiveness. Existing economic evaluations of LVADs for these patients have limitations. This study aimed to estimate the cost-effectiveness of LVADs as destination therapy, compared to optimal medical therapy, in the UK.

Methods

A cost-utility analysis from a UK healthcare perspective was conducted, using a Markov model. The model incorporated the impact of major events and complications. Sub-group analyses considered different severities of heart failure on cost-effectiveness. Uncertainty was measured in deterministic and probabilistic sensitivity analyses.

Results

LVAD produced additional 2.78 (95% CI 2.46–3.14) QALYs at an incremental cost of £152,329 (95% CI £125,665 - £181,812) compared to medical management, giving an incremental cost-effectiveness ratio (ICER) of £54,748 per QALY. The ICER remained above the accepted thresholds of cost-effectiveness in the UK if a small proportion of patients receiving LVAD becomes eligible for a heart transplant and for all subgroups based on heart failure severity. The deterministic sensitivity analysis showed that the ongoing outpatient costs had a significant impact on the results.

Conclusions

Our analysis found that LVADs are not cost-effective as destination therapy in the UK if a willingness to pay threshold of £50,000 per QALY gained or disease severity modifiers, were applied. Robust data on ongoing costs for LVAD and medical management are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesCost-Benefit AnalysisHeart FailureModels, EconomicQuality-Adjusted Life YearsHumansUnited KingdomMarkov ChainsMaleFemaleMiddle Aged

Autor:innen und Institutionen

  • Department of Applied Health Research, University College London, London, United Kingdom.
  • University of Birmingham, Birmingham, United Kingdom.
  • University of Birmingham Hospitals, Birmingham, United Kingdom.
  • Department of Public Health, Canadian University Dubai, Dubai, United Arab Emirates.

ORCID-Profile: Tuba Saygın Avşar, David Quinn

Förderung

  • Health Technology Assessment Programme

Zitieren

APA

Saygın Avşar, T., Jackson, L., Barton, P., Beese, S., Lim, H. S., Quinn, D., Price, M., & Moor, D. J. (2024). Cost-effectiveness of Left Ventricular Assist Devices (LVADs) as destination therapy in the UK: An economic modelling study. PLOS ONE. https://doi.org/10.1371/journal.pone.0312912

Vancouver

Saygın Avşar T, Jackson L, Barton P, Beese S, Lim HS, Quinn D, et al. Cost-effectiveness of Left Ventricular Assist Devices (LVADs) as destination therapy in the UK: An economic modelling study. PLOS ONE. 2024. doi:10.1371/journal.pone.0312912

BibTeX
@article{SaygnAvar2024,
  author = {Saygın Avşar, Tuba and Jackson, Louise and Barton, Pelham and Beese, Sophie and Lim, Hoong S and Quinn, David and Price, Malcolm and Moor, David J},
  title = {Cost-effectiveness of Left Ventricular Assist Devices (LVADs) as destination therapy in the UK: An economic modelling study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0312912}
}
Kostenlos starten →